Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
Tuberculosis, Volume 93, No. 2, Year 2013
Notification
URL copied to clipboard!
Description
Background: New tuberculosis (TB) vaccines are being developed to combat the global epidemic. A phase IIb trial of a candidate vaccine, MVA85A, was conducted in a high burden setting in South Africa to evaluate proof-of-concept efficacy for prevention of TB in infants. Objective: To describe the study design and implementation lessons from an infant TB vaccine efficacy trial. Methods: This was a randomised, controlled, double-blind clinical trial comparing the safety and efficacy of MVA85A to Candin control administered to 4-6-month-old, BCG-vaccinated, HIV-negative infants at a rural site in South Africa. Infants were followed up for 15-39 months for incident TB disease based on pre-specified endpoints. Results: 2797 infants were enrolled over 22 months. Factors adversely affecting recruitment and the solutions that were implemented are discussed. Slow case accrual led to six months extension of trial follow up. Conclusion: The clinical, regulatory and research environment for modern efficacy trials of new TB vaccines are substantially different to that when BCG vaccine was first evaluated in infants. Future infant TB vaccine trials will need to allocate sufficient resources and optimise operational efficiency. A stringent TB case definition is necessary to maximize specificity, and TB case accrual must be monitored closely. © 2012 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Tameris, Michele D.
South Africa, Cape Town
University of Cape Town
McShane, Helen
United Kingdom, Oxford
University of Oxford
McClain, John Bruce Lundy
United States, Rockville
Aeras
Landry, Bernard S.
United States, Rockville
Aeras
Lockhart, Stephen P.
Unknown Affiliation
Luabeya, Angelique Kany Kany
South Africa, Cape Town
University of Cape Town
Geldenhuys, Hennie D.
South Africa, Cape Town
University of Cape Town
Shea, Jacqueline E.
Unknown Affiliation
Hussey, Greg Dudley
South Africa, Cape Town
University of Cape Town
van der Merwe, Linda
South Africa, Cape Town
University of Cape Town
de Kock, Marwou
South Africa, Cape Town
University of Cape Town
Scriba, Thomas J.
South Africa, Cape Town
University of Cape Town
Walker, Robert
United States, Rockville
Aeras
Hanekom, Willem Albert
South Africa, Cape Town
University of Cape Town
Hatherill, Mark
South Africa, Cape Town
University of Cape Town
Mahomed, Hassan
South Africa, Cape Town
University of Cape Town
Statistics
Citations: 40
Authors: 16
Affiliations: 3
Identifiers
Doi:
10.1016/j.tube.2013.01.003
ISSN:
14729792
e-ISSN:
1873281X
Research Areas
Disability
Infectious Diseases
Maternal And Child Health
Study Locations
South Africa